Aseptic necrosis of the jaw when using bisphosphonates: etiopathogenetic and preventive aspects

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article analyzes modern scientific research on bisphosphonate-associated osteonecrosis of the jaw (BONJ). It has been shown that a significant place in the etiology of BONJ is occupied by the features of the craniofacial region, as well as microbial infections, periodontal diseases in addition to tooth extraction, implant placement and other dental interventions. It has been revealed that a great importance in the pathogenesis of BONJ is attached to a change in cellular immunity, a negative effect on angiogenesis. In order to prevent BONJ, an integrated approach is proposed (a doctor prescribing treatment; a dentist; a periodontist and a dental hygienist) to the management of patients undergoing Bisphosphonates therapy, observing the time between taking Bisphosphonates and dental interventions, oral sanitation, patient education and raising awareness of doctors in the field of BONJ. Further clinical and basic scientific research is needed to gain a more complete understanding of the pathophysiology underlying BONJ and prevention methods.

Full Text

Restricted Access

About the authors

T. V. Potupchik

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0003-1133-4447
SPIN-code: 8353-3513

Candidate of Medical Sciences

Russian Federation, Krasnoyarsk

E. V. Kapustina

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia; Krasnoyarsk Regional Clinical Hospital

Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0001-9528-2781
SPIN-code: 3716-9832

Сandidate of Medical Sciences

Russian Federation, Krasnoyarsk; Krasnoyarsk

V. V. Oskina

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
ORCID iD: 0009-0002-0741-5316
Russian Federation, Krasnoyarsk

L. N. Boeva

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia; Krasnoyarsk Regional Clinical Hospital

Email: potupchik_tatyana@mail.ru
ORCID iD: 0009-0000-1478-4369
SPIN-code: 2749-4424

Сandidate of Medical Sciences

Russian Federation, Krasnoyarsk; Krasnoyarsk

References

  1. Prueter J., Dildeep A. Bisphosphonate related osteonecrosis of calvarial bone. Am J Otolaryngol. 2016; 37 (5): 470–2. doi: 10.1016/j.amjoto.2016.05.002
  2. Yarom N., Shapiro C.L., Peterson D.E. et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol. 2019; 37 (25): 2270–90. doi: 10.1200/JCO.19.01186
  3. Ruggiero S.L., Dodson T.B., Aghaloo T. et al. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg. 2022; 80 (5): 920943. doi: 10.1016/j.joms.2022.02.008
  4. Bensi C., Giovacchini F., Lomurno G. et al. Quality of life in patients affected by medication-related osteonecrosis of the jaws: A systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021; 132 (2): 182–9. doi: 10.1016/j.oooo.2021.03.006
  5. Tenore G., Mohsen A., Rossi A.F. et al. Does medication-related osteonecrosis of the jaw influence the quality of life of cancer patients? Biomedicine. 2020; 8 (4): 95. doi: 10.3390/biomedicines8040095
  6. Adachi N., Ayukawa Y., Yasunami N. et al. Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw. Sci Rep. 2020; 10 (1): 5620. doi: 10.1038/s41598-020-61724-6
  7. Aguirre J.I., Castillo E.J., Kimmel D.B. Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (MRONJ). Bone. 2021; 153: 116168. doi: 10.1016/j.bone.2021.116168
  8. Aguirre J.I., Castillo E.J., Kimmel D.B. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone. 2021; 153: 116184. doi: 10.1016/j.bone.2021.116184
  9. Akita Y., Kuroshima S., Nakajima K. et al. Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice. J Bone Miner Metab. 2018; 36 (5): 547–59. doi: 10.1007/s00774-017-0872-1
  10. Biguetti C.C., De Oliva A.H., Healy K. et al. Medication-related osteonecrosis of the jaws after tooth extraction in senescent female mice treated with zoledronic acid: Microtomographic, histological and immunohistochemical characterization. PLoS One. 2019; 14 (6): e0214173. doi: 10.1371/journal.pone.0214173
  11. Castillo E.J., Messer J.G., Abraham A.M. et al. Preventing or controlling periodontitis reduces the occurrence of osteonecrosis of the jaw (ONJ) in rice rats (Oryzomyspalustris). Bone. 2021; 145: 115866. doi: 10.1016/j.bone.2021.115866
  12. Kozutsumi R., Kuroshima S., Kaneko H. et al. Zoledronic acid deteriorates soft and hard tissue healing of murine tooth extraction sockets in a dose-dependent manner. Calcif Tissue Int. 2022; 110 (1): 104–16. doi: 10.1007/s00223-021-00890-9
  13. Otto S., Pautke C., Arens D. et al. A drug holiday reduces the frequency and severity of medication-related osteonecrosis of the jaw in a minipig model. J Bone Miner Res. 2020; 35 (11): 2179–92. doi: 10.1002/jbmr.4119
  14. Тимченко Т.П. Бисфосфонаты как потенциальные ингибиторы кальцификации биопротезов клапанов сердца (обзор). Современные технологии в медицине. 2022; 14 (2): 68–78 [Timchenko T.P. Bisphosphonates as potential inhibitors of calcification of bioprosthesis heart valves (review). Modern technologies in medicine. 2022; 14 (2): 68–78 (in Russ.)]. doi: 10.17691/stm2022.14.2.07
  15. Watts N.B., Chessnut C.H., Genant H.K. et al. History of etidronate. Bone. 2020; 134: 115222. doi: 10.1016/j.bone.2020.115222
  16. Papapoulos S.E. Pamidronate: a model compound of the pharmacology of nitrogen-containing bisphosphonates; a Leiden historical perspective. Bone. 2020; 134: 115244. doi: 10.1016/j.bone.2020.115244
  17. Потупчик Т.В., Веселова О.Ф., Тутынин А.К. и др. Профилактика и лечение остеопороза у коморбидных пациентов. Врач. 2024; 35 (8): 13–21 [Potupchik T., Veselova O., Tutynin A. et al. Prevention and treatment of osteoporosis in comorbid patients. Vrach. 2024; 35 (8): 13–21 (in Russ.)]. doi: 10.29296/25877305-2024-08-03
  18. Abdik H., Avşar Abdik E., Demirci S. et al. The effects of bisphosphonates on osteonecrosis of jaw bone: A stem cell perspective. Mol Biol Rep. 2019; 46 (1): 763–76. doi: 10.1007/s11033-018-4532-x
  19. Gong X., Yu W., Zhao H. et al. Skeletal site-specific effects of zoledronate on in vivo bone remodeling and in vitro BMSCs osteogenic activity. Sci Rep. 2017; 7: 36129. doi: 10.1038/srep36129
  20. Vermeer J., Renders G., van Duin M.A. et al. Bone-site-specific responses to zoledronic acid. Oral Dis. 2017; 23 (1): 126–33. doi: 10.1111/odi.12587
  21. Preidl R., Amann K., Weber M. Lineage-associated connexin 43 expression in bisphosphonate-exposed rat bones. J Craniomaxillofacial Surg. 2021; 49 (8): 738–47. doi: 10.1016/j.jcms.2021.02.010
  22. George E.L., Lin Y.L., Saunders M.M. Bisphosphonate-related osteonecrosis of the jaw: A mechanobiology perspective. Bone Rep. 2018; 8: 104–9. doi: 10.1016/j.bonr.2018.03.003
  23. Heim N., Götz W., Kramer F.J. et al. Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients. Dentomaxillofacial Radiol. 2019; 48 (8): 20190132. doi: 10.1259/dmfr.20190132
  24. Kuroshima S., Al-Salihi Z., Yamashita J. Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow. Clin Oral Investig. 2016; 20 (4): 727–36. doi: 10.1007/s00784-015-1550-0
  25. Chang J., Hakam AE., McCauley L. Current understanding of the pathophysiology of osteonecrosis of the jaw. Cur Osteoporos Rep. 2018; 16 (5): 584–95. doi: 10.1007/s11914-018-0474-4
  26. Otto S., Aljohani S., Fliefel R. et al. Infection as an important factor in medication-related osteonecrosis of the jaw (MRONJ). Medicina (Kaunas). 2021; 57 (5): 463. doi: 10.3390/medicina57050463
  27. Cerrato A., Zanette G., Boccuto M. et al. Actinomyces and MRONJ: A retrospective study and a literature review. J Stomatol Oral Maxillofac Surg. 2021; 122 (5): 499–504. doi: 10.1016/j.jormas.2020.07.012
  28. Kwoen M.J., Park J.H., Kim K.S. et al. Association between periodontal disease, tooth extraction, and medication-related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort-based study. J Periodontol. 2023; 94 (1): 98–107. doi: 10.1002/JPER.21-0611
  29. McCormick B., Chu J.Y., Vermeren, S. Cross-talk between Rho GTPases and PI3K in the neutrophil. Small GTPases. 2019; 10 (3): 187–95. doi: 10.1080/21541248.2017.1304855
  30. Chadwick J.W., Tenenbaum H.C., Sun C.X. et al. The effect of pamidronate delivery in bisphosphonate-naive patients on neutrophil chemotaxis and oxidative burst. Sci Rep. 2020; 10 (1): 18309. doi: 10.1038/s41598-020-75272-6
  31. Movila A., Ishii T., Albassam A. et al. Macrophage migration inhibitory factor (MIF) supports homing of osteoclast precursors to peripheral osteolytic lesions. J Bone Miner Res. 2016; 31 (9): 1688–700. doi: 10.1002/jbmr.2854
  32. Hoefert S., Sade Hoefert C., Munz A. et al. Effect of bisphosphonates on macrophagic THP-1 cell survival in bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Surg Oral Med Oral Pathol Oral Radiol. 2016; 121 (3): 222–32. doi: 10.1016/j.oooo.2015.10.008
  33. Zhu W., Xu R., Du J. et al. Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J. 2019; 33 (4): 5208–19. doi: 10.1096/fj.201801791RR
  34. Hayano H., Kuroshima S., Sasaki M. et al. Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice. Bone. 2020; 135: 115308. doi: 10.1016/j.bone.2020.115308
  35. Allegra A., Innao V., Pulvirenti N. et al. Antiresorptive agents and anti-angiogenesis drugs in the development of osteonecrosis of the jaw. The Tohoku J Exp Med. 2019; 248 (1): 27–9. doi: 10.1620/tjem.248.27
  36. Imada M., Yagyuu T., Ueyama Y. et al. Prevention of tooth extraction-triggered bisphosphonate-related osteonecrosis of the jaws with basic fibroblast growth factor: An experimental study in rats. PLoS One. 2019; 14 (2): e0211928. doi: 10.1371/journal.pone.0211928
  37. Kim S., Williams D.W., Lee C. et al. IL-36 induces bisphosphonate-related osteonecrosis of the jaw-like lesions in mice by inhibiting TGF-β-mediated collagen expression. J Bone Miner Res. 2017; 32 (2): 309–18. doi: 10.1002/jbmr.2985
  38. Tamari T., Elimelech R., Cohen G. et al. Endothelial progenitor cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy. Sci Rep. 2019; 9 (1): 18896. doi: 10.1038/s41598-019-55383-5
  39. Kambara Y., Kobayashi E., Katsuragi H. et al. Effects of zoledronic acid on human gingival fibroblasts and human umbilical vein endothelial cells. J Hard Tissue Biol. 2021; 30 (2): 123–30. doi: 10.2485/jhtb.30.123
  40. De Ponte F.S., Catalfamo L., Micali G. et al. Effect of bisphosphonates on the mandibular bone and gingival epithelium of rats without tooth extraction. Exp Ther Med. 2016; 11 (5): 1678–84. doi: 10.3892/etm.2016.3168
  41. Фомичев Е.В., Кирпичников М.В., Ярыгина Е.Н. и др. Бисфосфонатные остеонекрозы челюстей. Вестник Волгоградского государственного медицинского университета. 2019; 1 (69): 3–7 [Fomichev E.V., Kirpichnikov M.V., Yarygina E.N. et al. Bisphosphonate osteonecrosis of the jaws. Bulletin of the Volgograd State Medical University. 2019; 1 (69): 3–7 (in Russ.)]. doi: 10.19163/1994-9480-2019-1(69)-3-8
  42. AlRowis R., Aldawood A., AlOtaibi M. et al. Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies. Saudi Dent J. 2022; 34 (3): 202–10. doi: 10.1016/j.sdentj.2022.01.003
  43. Beth-Tasdogan N.H., Mayer B., Hussein H. et al. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022; 7 (7): CD012432. doi: 10.1002/14651858.CD012432.pub3
  44. Taguchi A., Uemura Y., Imai T. et al. Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. Adequate Treatment of Osteoporosis (A-TOP) research group. J Bone Miner Metab. 2019; 37 (5): 886–92. doi: 10.1007/s00774-019-00990-5
  45. Landi L., Leali P.T., Barbato L. et al. Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP). J Orthop Traumatol. 2023; 24 (1): 36. doi: 10.1186/s10195-023-00713-7
  46. Saur F.G., Keinki C., Cramer A. et al. Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone-Stabilizing Drugs. J Clin Exp Dent Res. 2024; 10 (6): e70024. doi: 10.1002/cre2.70024
  47. Moharamzadeh K. Bisphosphonates and Medication-Related Osteonecrosis of the Jaw. In book: Diseases and Conditions in Dentistry. 2018; pp. 33–6. doi: 10.1002/9781119312093.ch4
  48. Брудян Г.С., Хабибулина М.М., Струков В.И. и др. Остеоинтеграция зубных имплантатов при климактерическом остеопорозе: стратегии оптимизации, пути и перспективы решения проблемы. Врач. 2023; 34 (7): 80–6 [Brudyan G., Khabibulina M., Strukov V. et al. Osteointegration of dental implants in menopausal osteoporosis: optimization strategies, ways and prospects of solving the problem. Vrach. 2023; 34 (7): 80–6 (in Russ.)]. doi: 10.29296/25877305-2023-07-18
  49. Hristamyan-Cilev M.A., Pechalova P.P., Raycheva R.D. et al. Bisphosphonate-associated Osteonecrosis of the Jaws: a Survey of the Level of Knowledge of Dentists about the Risks of Bisphosphonate Therapy. Folia Med (Plovdiv). 2019; 61 (2): 303–11. doi: 10.2478/folmed-2018-0075
  50. Iijima Y., Yamada M., Amano M. et al. Dental Hygienists’ Awareness of Medication-Related Osteonecrosis of the Jaw in Private Dental Clinics in Japan. Gerontol Geriatr Med. 2024; 10: 23337214241292794. doi: 10.1177/23337214241292794

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russkiy Vrach Publishing House